Profound Medical Corp.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Arun Swarup Menawat
- Full Time Employees
- 142
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 2400 Skymark Avenue Mississauga ON Canada L4W 5K5
- IPO Date
- Oct 29, 2019
- CIK
- 0001628808
- Website
- profoundmedical.com
- Similar Companies
- Business
- Profound Medical Corp. is a medical device company specializing in the development and commercialization of advanced, non-invasive MR-guided high-intensity focused ultrasound (HIFU) therapy systems. Its primary products include the Sonalleve MR-HIFU system for the treatment of symptomatic uterine fibroids and various other soft tissue tumors; the ExAblate Neuro system for neurological disorders; and MR-HIFU systems for pain palliation and ablation of tumors. The company provides integrated hardware and software solutions combining magnetic resonance imaging (MRI) with focused ultrasound technologies to enable precise, non-invasive therapeutic interventions. Profound Medical operates primarily in markets across North America, Europe, and Asia, targeting healthcare providers such as hospitals and specialized treatment centers. Founded in 2012 and headquartered in Toronto, Canada, Profound Medical has recently focused on strategic growth through enhancing its product pipeline and expanding clinical applications for its MR-HIFU technology. In the last 1-2 years, the company has strengthened partnerships within the medical technology ecosystem, advanced regulatory clearances, and pursued new indications for its therapy systems. It has also made operational strides to broaden its global footprint and augment sales and distribution networks to better serve its target markets. These recent developments represent a strategic expansion aimed at cementing Profound Medical's position as an innovative leader in non-invasive therapeutic ultrasound technologies within the healthcare industry. The company’s industry classification includes medical devices and healthcare technology, with business segments encompassing product development, manufacturing, sales, and clinical support services. Its target customers are primarily healthcare institutions and practitioners specializing in oncology, gynecology, pain management, and neurology. Profound Medical maintains a focus on research and development to continuously innovate its therapeutic platforms and strengthen clinical outcomes. It operates subsidiaries and collaborates with contract manufacturers and clinical research organizations to support its operations worldwide.
Wall Street Analysts See a 59.68% Upside in Profound Medical (PROF): Can the Stock Really Move This High?
Profound to Showcase TULSA-PRO®, the TULSA Procedure™ and the Future of iMRI at AUA2026
Profound Medical Annual General and Special Meeting of Shareholders Voting Results
Profound Medical Q1 Earnings Call Highlights
Profound Medical Corp. (PRN:CA) Q1 2026 Earnings Call Transcript
Profound Medical (PROF) Reports Q1 Loss, Tops Revenue Estimates
Profound Medical Reports Strong First Quarter 2026 Financial Results
Profound Medical Showcases TULSA Data, AI Software Upgrades, and Reimbursement Tailwinds at Conference
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF
Profound Medical to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference
Profound Medical Corp. Investigated by the Portnoy Law Firm
Contrasting Profound Medical (NASDAQ:PROF) and Cosmos Health (NASDAQ:COSM)
Incision-Free, MRI-Guided Prostate Treatment with Profound's TULSA-PRO® to be Featured in Multiple Presentations at the Upcoming 2026 Society of Interventional Radiology Scientific Meeting
Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure™ Milestone
Profound Medical (PROF) Surges 13.0%: Is This an Indication of Further Gains?
Profound Medical Corp. (PRN:CA) Discusses First Clinical Outcomes and Precision of TULSA from the CAPTAIN Trial in Prostate Cancer Transcript
CAPTAIN Trial Comparing Profound's MRI-Guided TULSA Procedure™ to Robotic Radical Prostatectomy Successfully Meets Primary Safety Endpoint, Preservation of Erectile Function and Urinary Continence
Profound Medical Corp. (PRN:CA) Q4 2025 Earnings Call Transcript
Profound Medical (PROF) Reports Q4 Loss, Misses Revenue Estimates
Earnings Preview: Profound Medical (PROF) Q4 Earnings Expected to Decline